三诺生物：公司第二代CGM2025年开始在国内上市销售

Core Viewpoint - Sanofi Biologics has received domestic Class III medical device registration for its second-generation Continuous Glucose Monitoring (CGM) system, expected to launch in the domestic market in 2025, while actively pursuing global registration efforts [1] Production Capacity - The current production capacity is sufficient to meet existing market demand, with the company demonstrating flexibility to adjust capacity in response to future demand growth [1] - The company has established semi-automated and fully automated production lines for CGM, allowing for dynamic adjustments in output based on business development and sales needs [1]